Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:38:46 EST Thu 22 Jan 2026
Enter Symbol
or Name
USA
CA



Q:REGN - REGENERON PHARMACEUTICALS INC - https://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q1.6750.00·762.985.2749.330.859414    821.11  476.486908:16:07Jan 2115 min RT 2¢

Recent Trades - Last 10 of 14
Time ETExPriceChangeVolume
08:16:07Q749.33 1
08:08:46Q754.004.675
08:06:05Q750.000.6715
08:02:34Q749.33 1
08:00:32Q749.33 1
08:00:08Q749.82150.49151
08:00:05Q749.33 2
08:00:05Q745.5482-3.78181
08:00:02Q768.9919.6615
08:00:02Q751.001.67455

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-21 12:00U:REGNNews ReleaseNation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
2026-01-02 16:05U:REGNNews ReleaseRegeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
2025-12-23 01:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
2025-12-22 16:05U:REGNNews ReleaseRegeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-07 16:30U:REGNNews ReleaseLynozyfic(TM) (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
2025-12-01 07:00U:REGNNews ReleaseRegeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
2025-11-25 01:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
2025-11-19 16:10U:REGNNews ReleaseEYLEA HD(TM) (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
2025-11-19 07:00U:REGNNews ReleaseLibtayo(TM) (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
2025-11-13 07:00U:REGNNews ReleaseRegeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
2025-11-08 10:47U:REGNNews ReleasePhase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
2025-11-07 08:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
2025-11-03 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2025-10-31 07:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
2025-10-29 08:00U:REGNNews ReleaseOPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
2025-10-28 06:30U:REGNNews ReleaseRegeneron Reports Third Quarter 2025 Financial and Operating Results
2025-10-17 07:30U:REGNNews ReleaseLibtayo(TM) (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
2025-10-15 07:01U:REGNNews ReleaseRegeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
2025-10-12 10:19U:REGNNews ReleaseDB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss